Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Glatiramer promotes oligodendroglial cell maturation in a cuprizone-induced demyelination model.
Episode 43 with Dr. May Han on following patients through the course of their disease
Defining the clinical course of multiple sclerosis: The 2013 revisions.
A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS).
The Role of the Gut Microbiome on Multiple Sclerosis Risk and Progression
Development of oral immunomodulatory agents in the management of multiple sclerosis.
Sustained cortical and subcortical neuromodulation induced by electrical tongue stimulation.
Brain MRI results of DECIDE: a randomized, double-blind trial of DAC HYP vs. IFNβ-1a in RRMS patients
The Oxford English Corpus: Facts about the language, The Story of Dictionaries
Episode 36 with Dr. Jenny Ting on the inflammasome
American Academy of Neurology Fall Conference 2014
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
The complex role of estrogens in inflammation.
A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis.
ACTRIMS-ECTRIMS 2014 -- Day 4
Suppression of CD4+ T cell activation by a novel inhibitor of Src family kinases.
Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells.
Differential effects of interferon-β1b on cytokine patterns of CD4+ and CD8+ T cells derived from RRMS and PPMS patients.
A timing-of-birth effect on multiple sclerosis clinical phenotype.
INF-β1b therapy modulates L-arginine and nitric oxide metabolism in patients with relapse remittent multiple sclerosis.
Teriflunomide for multiple sclerosis.
Phase III study: Ocrelizumab significantly reduces disease activity in PPMS patients
IFN-β Treatment Requires B Cells for Efficacy in Neuroautoimmunity.
CSF Metabolite Analysis May Offer Sensitive Biomarkers for MS
Estriol preserves synaptic transmission in the hippocampus during autoimmune demyelinating disease.

Pages